BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36964109)

  • 21. Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group.
    Malapelle U; Donne AD; Pagni F; Fraggetta F; Rocco EG; Pasello G; Perrone G; Pepe F; Vatrano S; Pignata S; Pinto C; Pruneri G; Russo A; Soto Parra HJ; Vallone S; Marchetti A; Troncone G; Novello S
    Crit Rev Oncol Hematol; 2024 Jan; 193():104217. PubMed ID: 38040072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
    Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
    Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and breakdown of EGFR exon 20 driver mutations in routine NHS lung cancer diagnostic testing.
    Moore DA; Balbi KJ; Poskitt B; Bennett P
    J Clin Pathol; 2022 Mar; 75(3):209-210. PubMed ID: 34168072
    [No Abstract]   [Full Text] [Related]  

  • 24. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive testing in non-small cell lung carcinoma.
    Dundr P; Matěj R; Němejcová K; Bártů M; Stružinská I
    Klin Onkol; 2021; 34(Supplementum 1):29-34. PubMed ID: 34154327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice: A Cross-Platform Comparison of Three Different Molecular Methods for Mutation Detection.
    Bartels S; Persing S; Hasemeier B; Schipper E; Kreipe H; Lehmann U
    J Mol Diagn; 2017 Sep; 19(5):722-732. PubMed ID: 28723342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).
    de Biase D; Visani M; Malapelle U; Simonato F; Cesari V; Bellevicine C; Pession A; Troncone G; Fassina A; Tallini G
    PLoS One; 2013; 8(12):e83607. PubMed ID: 24376723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation, Validation, and Implementation of the Idylla System as Rapid Molecular Testing for Precision Medicine.
    Huang H; Springborn S; Haug K; Bartow K; Samra H; Menon S; Mackinnon AC
    J Mol Diagn; 2019 Sep; 21(5):862-872. PubMed ID: 31443844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relevance of tumor mutation profiling in interpretation of NGS data from cell-free DNA in non-small cell lung cancer patients.
    Ottestad AL; Wahl SGF; Grønberg BH; Skorpen F; Dai HY
    Exp Mol Pathol; 2020 Feb; 112():104347. PubMed ID: 31759951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.
    Scilla KA; Rolfo C
    Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer.
    Riely GL
    J Natl Compr Canc Netw; 2017 May; 15(5S):686-688. PubMed ID: 28515244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implementing Genomic Testing for Lung Cancer Into Routine Clinical Practice - The Welsh Experience.
    Cox S; Powell C; Morgan S
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):716-723. PubMed ID: 36088167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LungCARD - Report on worldwide research and clinical practices related to lung cancer.
    Jankovic R; J Goncalves H; Cavic M; Clemente C; Lind M; Murillo Carrasco A; Nadifi S; Khyatti M; Adebambo T; Egamberdiev D
    J BUON; 2019; 24(1):11-19. PubMed ID: 30941946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.
    Mondaca S; Lebow ES; Namakydoust A; Razavi P; Reis-Filho JS; Shen R; Offin M; Tu HY; Murciano-Goroff Y; Xu C; Makhnin A; Martinez A; Pavlakis N; Clarke S; Itchins M; Lee A; Rimner A; Gomez D; Rocco G; Chaft JE; Riely GJ; Rudin CM; Jones DR; Li M; Shaffer T; Hosseini SA; Bertucci C; Lim LP; Drilon A; Berger MF; Benayed R; Arcila ME; Isbell JM; Li BT
    Lung Cancer; 2021 Sep; 159():66-73. PubMed ID: 34311346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples.
    Pepe F; De Luca C; Smeraglio R; Pisapia P; Sgariglia R; Nacchio M; Russo M; Serra N; Rocco D; Battiloro C; Ambrosio F; Gragnano G; Vigliar E; Bellevicine C; Troncone G; Malapelle U
    J Clin Pathol; 2019 Jan; 72(1):38-45. PubMed ID: 30279174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of
    Bai H; Xia J; Zhao X; Gong Z; Zhang D; Xiong L
    J Clin Pathol; 2019 May; 72(5):379-385. PubMed ID: 30787028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
    Rizvi H; Sanchez-Vega F; La K; Chatila W; Jonsson P; Halpenny D; Plodkowski A; Long N; Sauter JL; Rekhtman N; Hollmann T; Schalper KA; Gainor JF; Shen R; Ni A; Arbour KC; Merghoub T; Wolchok J; Snyder A; Chaft JE; Kris MG; Rudin CM; Socci ND; Berger MF; Taylor BS; Zehir A; Solit DB; Arcila ME; Ladanyi M; Riely GJ; Schultz N; Hellmann MD
    J Clin Oncol; 2018 Mar; 36(7):633-641. PubMed ID: 29337640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021.
    Pisapia P; Costa JL; Pepe F; Russo G; Gragnano G; Russo A; Iaccarino A; de Miguel-Perez D; Serrano MJ; Denninghoff V; Quagliata L; Rolfo C; Malapelle U
    Crit Rev Oncol Hematol; 2021 May; 161():103311. PubMed ID: 33781866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Cell-Free DNA in Stage I-IV Non-Small Cell Lung Cancer.
    Jiang J; Adams HP; Yao L; Yaung S; Lal P; Balasubramanyam A; Fuhlbrück F; Tikoo N; Lovejoy AF; Froehler S; Fang LT; Achenbach HJ; Floegel R; Krügel R; Palma JF
    J Mol Diagn; 2020 Feb; 22(2):228-235. PubMed ID: 31837429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical next-generation sequencing in patients with non-small cell lung cancer.
    Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
    Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.